As of 2015, multiple sclerosis (MS) is the only treatable neurodegenerative disease. It has frequent visual manifestations, most of which are in the clinical purview of neuro-ophthalmologists. This syllabus is intended to update neuro-ophthalmologists about new data surrounding, the new and emerging disease modifying therapies, and the use of targeted symptomatic therapies available for treatment of common neuro-ophthalmologic complaints experienced by patients living with MS.
